In tumors with a moderate MMP-9 expression (e.g., prostate, pancreatic, and head and neck cancers), nanoprobes and other diagnostic tools can assess MMP-9 levels to guide personalized strategies [149], and MMP-9-targeted nanomedicines may still impede the disease progression. The gene discussed is MMP9; the disease is head and neck cancer.